Insider Selling: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider Sells 3,000 Shares of Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT) insider William Ho sold 3,000 shares of the stock in a transaction that occurred on Wednesday, October 13th. The stock was sold at an average price of $29.69, for a total value of $89,070.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

William Ho also recently made the following trade(s):

  • On Monday, September 20th, William Ho sold 2,000 shares of RAPT Therapeutics stock. The stock was sold at an average price of $40.00, for a total value of $80,000.00.
  • On Friday, September 17th, William Ho sold 2,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $38.97, for a total transaction of $77,940.00.
  • On Wednesday, September 8th, William Ho sold 3,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $36.04, for a total value of $108,120.00.
  • On Monday, August 16th, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $32.07, for a total transaction of $32,070.00.
  • On Monday, August 2nd, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $30.52, for a total transaction of $30,520.00.

Shares of RAPT traded up $1.70 during midday trading on Thursday, reaching $32.03. 2,559 shares of the stock were exchanged, compared to its average volume of 444,024. The stock’s 50 day simple moving average is $33.30 and its 200 day simple moving average is $28.24. The company has a market cap of $944.50 million, a P/E ratio of -13.39 and a beta of 0.04. RAPT Therapeutics, Inc. has a twelve month low of $14.63 and a twelve month high of $43.26.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Wednesday, August 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.05. RAPT Therapeutics had a negative net margin of 1,219.06% and a negative return on equity of 45.84%. The firm had revenue of $0.87 million during the quarter, compared to the consensus estimate of $1.43 million. Research analysts expect that RAPT Therapeutics, Inc. will post -2.64 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada increased its position in shares of RAPT Therapeutics by 89.2% in the second quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock worth $39,000 after purchasing an additional 580 shares during the period. Ameritas Investment Partners Inc. lifted its stake in RAPT Therapeutics by 45.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,409 shares of the company’s stock valued at $45,000 after purchasing an additional 440 shares during the last quarter. Citigroup Inc. lifted its stake in shares of RAPT Therapeutics by 99.1% in the 2nd quarter. Citigroup Inc. now owns 2,714 shares of the company’s stock valued at $86,000 after acquiring an additional 1,351 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of RAPT Therapeutics by 27.3% during the 2nd quarter. Legal & General Group Plc now owns 3,047 shares of the company’s stock valued at $96,000 after acquiring an additional 653 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new stake in RAPT Therapeutics during the 2nd quarter worth $169,000. 87.57% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 11th. SVB Leerink restated a “buy” rating on shares of RAPT Therapeutics in a research note on Monday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 price objective on shares of RAPT Therapeutics in a research report on Monday, August 30th. Finally, Piper Sandler initiated coverage on RAPT Therapeutics in a research note on Sunday, June 20th. They issued an “overweight” rating and a $61.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $59.86.

RAPT Therapeutics Company Profile

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Read More: Why is cost of goods sold important?

Insider Buying and Selling by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.